

**Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2022**

Sr. No	Particulars	Quarter Ended			Year Ended
		30.06.2022 (Unaudited)	31.03.2022 (Audited)	30.06.2021 (Unaudited)	31.03.2022 (Audited)
1	Revenue from Operations	2,209	1,824	2,106	7,822
2	Other Income	70	440	173	8,918
3	<b>Total Income</b>	<b>2,280</b>	<b>2,264</b>	<b>2,278</b>	<b>16,740</b>
4	<b>Expenses</b>				
	Cost of Materials Consumed	196	204	234	853
	Cost of Construction	461	255	248	1,164
	Changes in Inventories of Finished Goods and WIP	(2)	(34)	304	246
	Employee Benefit Expenses	621	545	547	2,147
	Finance Costs	11	10	10	39
	Depreciation and amortisation expense	167	140	113	486
	Other Expenses	392	562	341	2,020
	<b>Total Expenses</b>	<b>1,845</b>	<b>1,682</b>	<b>1,797</b>	<b>6,954</b>
5	<b>Profit Before Tax</b>	<b>434</b>	<b>582</b>	<b>481</b>	<b>9,786</b>
6	<b>Tax Expenses</b>				
	Current Tax	34	153	88	1,160
	Deferred Tax	15	(23)	8	21
	Short / (Excess) Provision of earlier years	-	(14)	-	(14)
7	<b>Net Profit after tax for the Period</b>	<b>385</b>	<b>465</b>	<b>384</b>	<b>8,619</b>
8	<b>Share of Associate's Profit/(Loss)</b>	<b>(2,241)</b>	<b>(374)</b>	<b>4,522</b>	<b>13,586</b>
9	<b>Net Profit after tax and Share of Associate's Profit</b>	<b>(1,855)</b>	<b>91</b>	<b>4,906</b>	<b>22,206</b>
10	<b>Other Comprehensive Income</b>				
	A (i) Items that will not be reclassified to Profit or (Loss)	(7,401)	878	(5,548)	11,897
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	841	(98)	650	(1,344)
	B (i) Items that will be reclassified to Profit or (Loss)	179	83	53	132
11	<b>Total Comprehensive Income/(Loss) for the Period</b>	<b>(8,237)</b>	<b>954</b>	<b>62</b>	<b>32,891</b>
12	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64
13	Other Equity (excluding Revaluation Reserve)				1,89,567
14	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	(0.72)	0.04	1.91	8.65



Alembic Limited  
Segment wise Consolidated Revenue and Results

Rs. In Lakhs

Sr. No	Particulars	Quarter Ended		Year Ended	
		30.06.2022 (Unaudited)	31.03.2022 (Audited)	30.06.2021 (Unaudited)	31.03.2022 (Audited)
1	<b>Segment Revenue</b>				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	729	698	1,092	3,227
	b. Real Estate Business	1,481	1,125	1,013	4,595
	<b>Total Income from Operations (Net)</b>	<b>2,209</b>	<b>1,824</b>	<b>2,106</b>	<b>7,822</b>
2	<b>Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)</b>				
	a. Active Pharmaceutical Ingredients Business	129	202	141	525
	b. Real Estate Business	353	323	277	1,162
	<b>Total</b>	<b>482</b>	<b>525</b>	<b>418</b>	<b>1,687</b>
	Unallocable Income and Expenditure				
	(i) Interest Expense	(11)	(10)	(10)	(39)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	(49)	(57)	69	7,960
	(iii) Other Income / (Expense)	13	124	4	178
	<b>Total Profit Before Tax</b>	<b>434</b>	<b>582</b>	<b>481</b>	<b>9,786</b>
3	<b>Segment Assets</b>				
	a. Active Pharmaceutical Ingredients Business	14,998	14,883	15,115	14,883
	b. Real Estate Business	28,199	27,248	22,416	27,248
	c. Unallocated	2,12,125	2,21,065	2,02,840	2,21,065
	<b>Total</b>	<b>2,55,321</b>	<b>2,63,195</b>	<b>2,40,370</b>	<b>2,63,195</b>
4	<b>Segment Liabilities</b>				
	a. Active Pharmaceutical Ingredients Business	1,963	1,752	1,896	1,752
	b. Real Estate Business	6,590	5,533	4,661	5,533
	c. Unallocated	5,347	6,251	4,048	6,251
	<b>Total</b>	<b>13,900</b>	<b>13,537</b>	<b>10,605</b>	<b>13,537</b>

**Notes:**

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The figures for quarter ended 31st March 2022 are the balancing figures between the audited figures in respect of full financial year ended 31st March 2022 and year to date unaudited figures up to the third quarter ended 31st December 2021.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara  
Date : 10th August, 2022



For Alembic Limited

Chirayu Amin  
Chairman



**Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2022**

Sr. No.	Particulars	Quarter Ended			Rs. in Lakhs
		30.06.2022 (Unaudited)	31.03.2022 (Audited)	30.06.2021 (Unaudited)	Year Ended 31.03.2022 (Audited)
1	Revenue from Operations	2,113	1,740	2,062	7,597
2	Other Income	71	433	173	8,909
3	<b>Total Income</b>	<b>2,184</b>	<b>2,172</b>	<b>2,235</b>	<b>16,506</b>
4	<b>Expenses</b>				
	Cost of Materials Consumed	196	204	234	853
	Cost of Construction	461	255	248	1,164
	Changes in Inventories of Finished Goods and WIP	(2)	(34)	304	246
	Employee Benefit Expenses	621	545	547	2,147
	Finance Costs	4	3	7	23
	Depreciation and amortisation expense	157	131	104	450
	Other Expenses	345	492	319	1,896
	<b>Total Expenses</b>	<b>1,782</b>	<b>1,596</b>	<b>1,764</b>	<b>6,779</b>
5	<b>Profit Before Tax</b>	<b>403</b>	<b>577</b>	<b>471</b>	<b>9,728</b>
6	<b>Tax Expenses</b>				
	Current Tax	24	152	88	1,150
	Deferred Tax	15	(23)	8	21
	Short / (Excess) Provision of earlier years	-	(15)	-	(15)
7	<b>Net Profit after tax for the Period</b>	<b>363</b>	<b>462</b>	<b>375</b>	<b>8,571</b>
8	<b>Other Comprehensive Income</b>				
	(i) Items that will not be reclassified to Profit or (Loss)	(7,373)	972	(5,392)	12,009
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	841	(115)	624	(1,364)
9	<b>Total Comprehensive Income/(Loss) for the Period</b>	<b>(6,169)</b>	<b>1,319</b>	<b>(4,394)</b>	<b>19,217</b>
10	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64
11	Other Equity (excluding Revaluation Reserve)				41,294
12	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	0.14	0.18	0.15	3.34



**Alembic Limited**  
**Segment wise Standalone Revenue and Results**

Rs. In Lakhs

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2022 (Unaudited)	31.03.2022 (Audited)	30.06.2021 (Unaudited)	31.03.2022 (Audited)
1	<b>Segment Revenue</b>				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	729	698	1,092	3,227
	b. Real Estate Business	1,384	1,041	969	4,371
	<b>Total Income from Operations (Net)</b>	<b>2,113</b>	<b>1,740</b>	<b>2,062</b>	<b>7,597</b>
2	<b>Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)</b>				
	a. Active Pharmaceutical Ingredients Business	129	202	141	525
	b. Real Estate Business	314	312	264	1,088
	<b>Total</b>	<b>443</b>	<b>514</b>	<b>406</b>	<b>1,613</b>
	Unallocable Income and Expenditure				
	(i) Interest Expense	(4)	(3)	(7)	(23)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	(49)	(57)	69	7,960
	(iii) Other Income / (Expense)	13	124	4	178
	<b>Total Profit Before Tax</b>	<b>403</b>	<b>577</b>	<b>471</b>	<b>9,728</b>
3	<b>Segment Assets</b>				
	a. Active Pharmaceutical Ingredients Business	14,998	14,883	15,115	14,883
	b. Real Estate Business	27,422	26,434	21,710	26,434
	c. Unallocated	66,252	73,102	51,836	73,102
	<b>Total</b>	<b>1,08,671</b>	<b>1,14,419</b>	<b>88,661</b>	<b>1,14,419</b>
4	<b>Segment Liabilities</b>				
	a. Active Pharmaceutical Ingredients Business	1,963	1,752	1,896	1,752
	b. Real Estate Business	6,075	4,972	4,434	4,972
	c. Unallocated	5,417	6,309	4,043	6,309
	<b>Total</b>	<b>13,456</b>	<b>13,034</b>	<b>10,373</b>	<b>13,034</b>

**Notes:**

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The figures for quarter ended 31st March 2022 are the balancing figures between the audited figures in respect of full financial year ended 31st March 2022 and year to date unaudited figures up to the third quarter ended 31st December 2021.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.

Place : Vadodara  
Date : 10th August, 2022



For Alembic Limited

Chirayu Amin  
Chairman



Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Alembic Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30<sup>th</sup> June, 2022 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable



VADODARA : The Nirat, 3rd Floor, 18, Windward Business Park, Behind Emerald One Complex, In The Lane of Dr. Prashant Buch, Jetalpur Road, Vadodara - 390 007  
● Tel: +91 265 234 3483, +91 265 235 4359 ● Email : vadodara@cnkindia.com

MUMBAI - HO : 3rd Floor, Mistry Bhavan, Dinshaw Vachha Road, Churchgate, Mumbai 400 020, India. ● Tel: +91 22 6623 0600

Website: [www.cnkindia.com](http://www.cnkindia.com)

MUMBAI | BENGALURU | CHENNAI | AHMEDABAD | GANDHINAGAR | DELHI | DUBAI | SHARJAH

4. The statement includes results of the following entities:
- Alembic City Limited (Subsidiary)
  - Alembic Pharmaceuticals Limited (Associate)
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose financial results reflect total revenue of Rs. 390.16 lakhs, total net loss after tax of Rs. 41.23 Lakhs and total comprehensive loss of Rs. 41.38 Lakhs for the quarter ended-30<sup>th</sup> June, 2022. The unaudited consolidated financial results also include the Group's share of net loss after tax of Rs. 2,240.90 Lakhs and total comprehensive loss of Rs. 2,089.93 lakhs (after adjusting impact of qualified opinion in the audit report on consolidated financial results) quarter ended 30<sup>th</sup> June, 2022, as considered in the statement, in respect of an associate. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

For C N K & Associates LLP  
Chartered Accountants  
Firm Registration No. 101961W/W-100036

 

Alok Shah  
Partner  
Membership No.042005  
Place: Vadodara  
Date: -10<sup>th</sup> August, 2022  
UDIN: 22042005AOSDWC6181

Independent Auditor's Review Report on Unaudited Standalone Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of **Alembic Limited** ("the Company") for the quarter ended 30<sup>th</sup> June, 2022 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



**VADODARA** : The Nirat, 3rd Floor, 18, Windward Business Park, Behind Emerald One Complex, In The Lane of Dr. Prashant Buch, Jetalpur Road, Vadodara - 390 007  
● Tel: +91 265 234 3483, +91 265 235 4359 ● Email : vadodara@cnkindia.com

**MUMBAI - HO** : 3rd Floor, Mistry Bhavan, Dinshaw Vachha Road, Churchgate, Mumbai 400 020, India. ● Tel: +91 22 6623 0600

Website: [www.cnkindia.com](http://www.cnkindia.com)

**MUMBAI | BENGALURU | CHENNAI | AHMEDABAD | GANDHINAGAR | DELHI | DUBAI | SHARJAH**

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For C N K & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036

*Alok Shah* *S. K. Shah*

Alok Shah

Partner

Membership No.042005

Place: Vadodara

Date: 10<sup>th</sup> August, 2022

UDIN: 22042005AOSDEY7170

